Anti-inflammatory effect of pristimerin on lipopolysaccharide-induced inflammatory responses in murine macrophages

Archives of Pharmacal Research

Volumn 36, Issue 4, 2013, Pages 495-500

  Kim, Hyeon Jin ^a   Park, Geun Mook ^a   Kim, Jin Kyung ^a  

^a Catholic University of Daegu   (South Korea)

Author keywords

Inflammation; Inflammatory response; Mitogen activated protein kinase; Nuclear factor kappa B; Pristimerin

Indexed keywords

CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PRISTIMERIN; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CELL VIABILITY; CLINICAL EVALUATION; CONTROLLED STUDY; DOWN REGULATION; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE; CELL SURVIVAL; CYCLOOXYGENASE 2; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES; MAP KINASE SIGNALING SYSTEM; MICE; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; TRITERPENES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84877876904     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-013-0054-1     Document Type: Article

References (25)

1. Bogdan, C. 2001. Nitric oxide and the immune response. Nature Immunology 2: 2907-2916.
2. Brown, J.R., and R.N. DuBois. 2005. COX-2: a molecular target for colorectal cancer prevention. Journal of Clinical Oncology 23: 2840-2855.
3. Carvalho, P.R., D.H. Silva, V.S. Bolzani, and M. Furlan. 2005. Antioxidant quinonemethide triterpenes from Salacia campestris. Chemistry & Biodiversity 2: 367-372.
4. Cook-Mills, J.M., and T.L. Deem. 2005. Active participation of endothelial cells in inflammation. Journal of Leukocyte Biology 77: 487-495.
5. Dirsch, V.M., A.K. Kiemer, H. Wagner, and A.M. Vollmar. 1997. The triterpenoid quinonemethide pristimerin inhibits induction of inducible nitric oxide synthase in murine macrophages. European Journal of Pharmacology 336: 211-217.
6. Eum, D.Y., J.Y. Byun, C.H. Yoon, W.D. Seo, K.H. Park, J.H. Lee, H.Y. Chung, S. An, Y. Suh, M.J. Kim, and S.J. Lee. 2011. Triterpenoid pristimerin synergizes with taxol to induce cervical cancer cell death through reactive oxygen species-mediated mitochondrial dysfunction. Anti-Cancer Drugs 22: 763-773.
7. Ferencik, M., V. Stvrtinova, I. Hulin, and M. Novak. 2007. Inflammation-a lifelong companion. Attempt at a non-analytical holistic view. Folia Microbiologica 52: 159-173.
8. Gomez, P.F., M.H. Pillinger, M. Atturm, N. Marjanovic, M. Dave, J. Park, C.O. Bingham, H. Al-Mussawir, and S.B. Abramson. 2005. Resolution of inflammation: prostaglandin E2 dissociates nuclear trafficking of individual NF-kappaB subunits (p65, p50) in stimulated rheumatoid synovial fibroblasts. Journal of Immunology 175: 6924-6930.
9. Ivashkiv, L.B. 2011. Inflammatory signaling in macrophages: transitions from acute to tolerant and alternative activation states. European Journal of Immunology 41: 2477-2481.
10. Johnson, G.L., and R. Lapadat. 2002. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298: 1911-1912.
11. Kirkwood, K.L., and C. Rossa. 2009. The potential of p38 MAPK inhibitors to modulate periodontal infections. Current Drug Metabolism 10: 55-67.
12. Krakauer, T. 2004. Molecular therapeutic targets in inflammation: cyclooxygenase and NF-kappaB. Current Drug Targets: Inflammation & Allergy 3: 317-324.
13. Lawrence, T., D.A. Willoughby, and D.W. Gilroy. 2002. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nature Reviews Immunology 2: 787-795.
14. Li, Q., and I.M. Verma. 2002. NF-κB regulation in the immune system. Nature Reviews Immunology 2: 725-734.
15. López, M.R., L. de León, and L. Moujir. 2011. Antibacterial properties of phenolic triterpenoids against Staphylococcus epidermidis. Planta Medica 77: 726-729.
16. Luo, D.Q., H. Wang, X. Tian, H.J. Shao, and J.K. Liu. 2005. Antifungal properties of pristimerin and celastrol isolated from Celastrus hypoleucus. Pest Management Science 61: 85-90.
17. Mu, X., W. Shi, L. Sun, H. Li, Z. Jiang, and L. Zhang. 2012. Pristimerin, a triterpenoid, inhibits tumor angiogenesis by targeting VEGFR2 activation. Molecules 17: 6854-6868.
18. Nam, N.H. 2006. Naturally occurring NF-kappaB inhibitors. Mini Reviews in Medicinal Chemistry 6: 945-951.
19. Petronelli, A., G. Pannitteri, and U. Testa. 2009. Triterpenoids as new promising anticancer drugs. Anti-Cancer Drugs 20: 880-892.
20. Qualtrough, D., A. Kaidi, S. Chell, H.N. Jabbour, A.C. Williams, and C. Paraskeva. 2007. Prostaglandin F(2alpha) stimulates motility and invasion in colorectal tumor cells. International Journal of Cancer 121: 734-740.
21. Sarkar, D., P. Saha, S. Gamre, S. Bhattacharjee, C. Hariharan, S. Ganguly, R. Sen, G. Mandal, S. Chattopadhyay, S. Majumdar, and M. Chatterjee. 2008. Anti-inflammatory effect of allylpyrocatechol in LPS-induced macrophages is mediated by suppression of iNOS and COX-2 via the NF-κB pathway. International Immunopharmacology 8: 1264-1271.
22. Sica, A., and A. Mantovani. 2012. Macrophage plasticity and polarization: in vivo veritas. The Journal of Clinical Investigation 122: 787-795.
23. Surh, Y.J., K.S. Chun, H.H. Cha, S.S. Han, Y.S. Keum, K.K. Park, and S.S. Lee. 2001. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutation Research 480-481: 243-268.
24. Wu, C.C., M.L. Chan, W.Y. Chen, C.Y. Tsai, F.R. Chang, and Y.C. Wu. 2005. Pristimerin induces caspase-dependent apoptosis in MDA-MB-231 cells via direct effects on mitochondria. Molecular Cancer Therapeutics 4: 1277-1285.
25. Zitvogel, L., O. Kepp, L. Galluzzi, and G. Kroemer. 2012. Inflammasomes in carcinogenesis and anticancer immune responses. Nature Immunology 13: 343-351.